CHICAGO––With Herceptin biosimilars on the horizon, Roche/Genentech Inc. is gearing up for the launch of two new breast cancer candidates – Perjeta and T-DM1 – as well as a subcutaneous formulation of Herceptin.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?